The SME initial public offering (IPO) of New Delhi-headquartered healthcare logistics, cold-chain phlebotomy, and diagnostic supply chain major Credent Connect N Care Limited (operating under its well-known logistics brand C3 Logistics) opened for public bidding across the national bourses today, Thursday, August 13, 2026.

Carrying an aggregate issue size of ₹93.90 crore set within a fixed price band parameter of ₹179 to ₹189 per share, the public offer marks one of the largest and most eagerly anticipated healthcare technology and logistics launches on the NSE Emerge SME platform this year.

By the close of its opening bidding session at 5:00 PM IST, central exchange matching engines logged valid electronic application tokens for 72,24,600 equity shares against a net public offer pool of 33,12,000 equity shares (excluding anchor allocations and market maker blocks). This places the issue at a strong opening Day 1 subscription baseline of 2.18 times.

Retail individual investors spearheaded the opening session volume surge, taking their dedicated quota past 3.11 times coverage on Day 1, while Qualified Institutional Buyers (QIBs) fully subscribed their reserved tranche right out of the gate at 1.00 time.

The multi-day public bidding window will remain open through Monday, August 17, 2026.

Here is an extended, plain-English human breakdown covering opening day subscription metrics, unlisted grey market trends, business operations across healthcare logistics and phlebotomy services, financial performance, valuation parameters, and key investment risk factors.

1. Day 1 Subscription Data Breakdown

By 5:00 PM on Day 1, central processing registries compiled total valid electronic application orders worth ₹136.54 crore (calculated at the upper price band cap of ₹189 per share), covering 218% of the net public offer.

The table below summarizes the opening session's demand metrics across all investor categories:

+-----------------------------------------------------------------------------------+
|               CREDENT CONNECT N CARE LIMITED: DAY 1 SUBSCRIPTION DATA             |
+-------------------+-----------------+------------------+------------------+-------+
| Category          | Shares Offered  | Shares Bid For   | Subscription (x) | Value |
+-------------------+-----------------+------------------+------------------+-------+
| QIB (Institutions)| 9,48,000        | 9,48,000         | 1.00x            | ₹17.92Cr
| NII / HNI (Wealth)| 7,08,000        | 11,25,000        | 1.59x            | ₹21.26Cr
| Retail (RII)      | 16,56,000       | 51,51,600        | 3.11x            | ₹97.37Cr
| Market Maker      | 2,52,000        | —                | —                | —     |
+-------------------+-----------------+------------------+------------------+-------+
| Total Net Offer   | 33,12,000       | 72,24,600        | 2.18x            | ₹136.54Cr
+-------------------+-----------------+------------------+------------------+-------+

Analyzing the Category Inflows:

  • Retail Individual Investors (RII - 3.11x): Everyday retail accounts generated the primary volume driver on Day 1. Retail applicants submitted electronic bids for 51,51,600 shares (8,586 application lots) against 16.56 lakh shares reserved for them, taking the retail tranche past full baseline coverage to 3.11 times (totaling ₹97.37 crore). Under the issue rules for this SME offer, retail applicants face a minimum lot requirement of 2 lots (1,200 shares), requiring an upfront application layout of ₹2,26,800 at ₹189 per share.
  • Non-Institutional Investors (NII / HNI - 1.59x): High-net-worth investors and family offices showed strong opening interest, submitting bids for 11,25,000 shares out of 7.08 lakh shares earmarked for their tranche, achieving 1.59 times coverage (totaling ₹21.26 crore). Small-HNI (applying for 3 lots / 1,800 shares = ₹3,40,200 minimum) and big-HNI accounts initiated active multi-lot orders.
  • Qualified Institutional Buyers (QIB - 1.00x): Institutional money desks opened their participation with complete baseline matching, placing orders for 9,48,000 shares out of 9.48 lakh offered (excluding anchor allocations), taking the net QIB tranche to 1.00 time (totaling ₹17.92 crore). A 1.00x institutional start on Day 1 shows genuine fund-level interest.
  • Market Maker Reserved Block: A dedicated block of 2,52,000 shares (~₹4.76 crore) is allocated to the designated market maker (Hem Finlease Private Limited) to support secondary market liquidity depth post-listing.

Marquee Institutional Anchor Allocation:

Prior to opening the public book-building window, Credent Connect N Care successfully raised ₹26.53 crore through its institutional anchor investor placement on Wednesday, August 12, 2026. A total of 14,04,000 equity shares were allocated to marquee anchor investors at the fixed upper cap price of ₹189 per share. Anchor participants included Sunil Singhania's Abakkus Venture Opportunities Fund, Motilal Oswal Finvest, Hem Growth Opportunities Fund, Mint Focussed Growth Fund, 360 ONE LVF Treasury Solutions Fund, and LRSD Securities, establishing strong institutional backing ahead of the public launch.

2. Unlisted Grey Market Premium (GMP) & Market Sentiment

In the unofficial grey market, sentiment surrounding Credent Connect N Care has been firmly bullish leading into its public launch:

  • Fixed Upper Price Cap Anchor: ₹189.00 per share
  • Current Grey Market Premium (GMP): Tracking around +₹50.00 per share
  • Estimated Listing Price Range: Expected debut counter level of ₹239.00 per share
  • Projected Listing Gain Margin: Indicating an immediate estimated listing upside of ~26.45%
  • Retail Minimum Application Lot Size: 2 Lots / 1,200 Shares (Minimum Investment: ₹2,26,800)

What Is Driving Grey Market Optimism?

The healthy grey market premium is primarily supported by two operational factors:

  1. Critical Specialized Healthcare Infrastructure: Cold-chain biological sample transit is a high-barrier business. Diagnostic chains cannot risk temperature spikes that ruin blood samples, giving established B2B players like Credent long-term contract stickiness.
  2. Massive Revenue & Profit Scaling in FY26: Revenue from operations surged 174.8% YoY to ₹214.16 crore in FY26, while net profit jumped to ₹18.45 crore, providing a solid fundamental backstop for secondary trading.

(Note: Grey market premiums represent informal, off-exchange quotes traded among dealers. They fluctuate based on daily market sentiment and broad equity benchmark trends, and should not be taken as a guaranteed listing return.)

3. Business Overview: What Does Credent Connect N Care Do?

Incorporated in June 2015 as Credent Cold Chain Logistics Private Limited and headquartered in New Delhi, Credent Connect N Care Limited is an integrated B2B healthcare services, temperature-controlled logistics, and phlebotomy workforce solutions provider.

Operating under its commercial brand C3 Logistics, the company serves as a vital back-end operational platform for diagnostic laboratories, In-Vitro Diagnostic (IVD) equipment manufacturers, pharmaceutical companies, hospitals, clinics, and corporate healthcare enterprises across India.

+-----------------------------------------------------------------------------------+
|                  CREDENT CONNECT N CARE BUSINESS AT A GLANCE                      |
+-----------------------------------+-----------------------------------------------+
| Commercial Operating Brand        | C3 Logistics                                  |
+-----------------------------------+-----------------------------------------------+
| Core Service Pillars              | Cold-Chain Diagnostic Sample Transit, Doorstep|
|                                   | Phlebotomy, Reagent Movement, Paramedic Staffing|
+-----------------------------------+-----------------------------------------------+
| B2B Client Ecosystem Depth        | Associated with 2,500+ Diagnostic Labs,       |
|                                   | IVD Companies, Hospitals & Pharma Majors      |
+-----------------------------------+-----------------------------------------------+
| Operational Field Workforce       | 6,500+ Trained Field Professionals &          |
|                                   | Temperature-Controlled Phlebotomy Riders      |
+-----------------------------------+-----------------------------------------------+
| Pan-India Network Reach           | Operating across 452+ Cities & Towns in India |
+-----------------------------------+-----------------------------------------------+
| Technology Integration            | IoT-Enabled Temperature Trackers, Real-Time   |
|                                   | TAT Monitoring & GPS Fleet Telematics         |
+-----------------------------------+-----------------------------------------------+

Core Competitive Moats:

1. High-Barrier Temperature-Controlled Cold Chain

Transporting blood, tissue, and biological specimens requires strict temperature maintenance (e.g., 2°C to 8°C or frozen below -20°C). Credent deploys IoT-enabled active cold boxes with real-time temperature telemetry logged on central cloud dashboards. If temperature fluctuates during transit, automated alerts trigger re-icing protocols, ensuring zero sample degradation before reaching central testing hubs.

2. Pan-India Phlebotomy & Last-Mile Field Force

With over 6,500 trained phlebotomists and field executives spanning 452+ cities, Credent handles doorstep home sample collection, stationed hospital phlebotomy, and corporate wellness health checkups. Diagnostic chains outsource home collection to Credent to avoid managing thousands of distributed on-field employees directly.

3. Deep Integration with Major Diagnostic Chains

Serving more than 2,500 laboratories and healthcare institutions creates high switching costs. Once a diagnostic network connects its central LIS (Laboratory Information System) software to Credent's logistics API for daily sample pickup routes, changing vendors risks logistical disruption and Turnaround Time (TAT) delays.

4. Detailed Financial Performance (FY24 to FY26)

An audit of Credent Connect N Care's restated consolidated financial statements reveals rapid top-line expansion alongside expanding operational and net profit margins over the last three fiscal years.

+-----------------------------------------------------------------------------------+
|               CREDENT CONNECT N CARE: 3-YEAR FINANCIAL PERFORMANCE                |
+-------------------------------+-------------------+-------------------+-----------+
| Financial Metric (₹ in Cr)    | FY24              | FY25              | FY26      |
+-------------------------------+-------------------+-------------------+-----------+
| Revenue from Operations       | 42.15             | 77.94             | 214.16    |
| Total Income                  | 42.28             | 78.10             | 214.43    |
| Operating EBITDA              | 2.85              | 4.99              | 28.46     |
| EBITDA Margin (%)             | 6.76%             | 6.40%             | 13.29%    |
| Net Profit After Tax (PAT)    | 1.82              | 3.61              | 18.45     |
| PAT Margin (%)                | 4.30%             | 4.62%             | 8.60%     |
| Total Debt / Borrowings       | 8.12              | 12.45             | ~24.50    |
| Net Worth                     | 11.20             | 16.85             | 48.20     |
| Return on Net Worth (RoNW %)  | 16.25%            | 21.42%            | 38.28%    |
+-------------------------------+-------------------+-------------------+-----------+

(Source: Official DRHP/RHP Filings & Restated Consolidated Statements)

Key Financial Observations:

  1. Explosive Top-Line Scaling: Operating revenue expanded from ₹42.15 crore in FY24 to ₹77.94 crore in FY25, before surging 174.8% YoY to ₹214.16 crore in FY26. Growth was driven by subsidiary consolidation, expanding B2B operations, supply chain management, and higher phlebotomy sample collection volumes.
  2. EBITDA & Net Profit Surge: Operating EBITDA jumped from ₹4.99 crore in FY25 to ₹28.46 crore in FY26 (EBITDA margin expanding from 6.40% to 13.29%), while net profit after tax (PAT) jumped from ₹3.61 crore to ₹18.45 crore (PAT margin expanding to 8.60%). Higher revenue density across existing cold-chain transit routes boosted operating leverage.
  3. High Return on Net Worth: Capital efficiency improved significantly, pushing the company's Return on Net Worth (RoNW) to 38.28% in FY26.

5. Structure of the Offer & Objects of the Issue

The ₹93.90 crore public offer is structured entirely as a fresh capital issue:

+-----------------------------------------------------------------------------------+
|                         IPO CAPITAL STRUCTURE BREAKDOWN                           |
+-----------------------------------+-----------------------------------------------+
| Total Issue Size                  | ₹93.90 Crore (49,68,000 Equity Shares)        |
+-----------------------------------+-----------------------------------------------+
| Fresh Issue Component             | ₹93.90 Crore (100% Fresh Capital Issue)       |
+-----------------------------------+-----------------------------------------------+
| Offer for Sale (OFS) Component    | ₹0.00 (No Selling Shareholders)               |
+-----------------------------------+-----------------------------------------------+
| Price Band                        | ₹179 to ₹189 per share                        |
+-----------------------------------+-----------------------------------------------+
| Face Value                        | ₹10 per share                                 |
+-----------------------------------+-----------------------------------------------+
| Market Maker Reserved Block       | 2,52,000 Shares (₹4.76 Crore Value)           |
+-----------------------------------+-----------------------------------------------+
| Lead Manager (BRLM)               | Hem Securities Limited                        |
+-----------------------------------+-----------------------------------------------+
| Registrar to the Issue            | KFin Technologies Limited                     |
+-----------------------------------+-----------------------------------------------+

How Will the Fresh Primary Capital Be Spent?

Because there is no Offer for Sale (OFS), 100% of the net proceeds will move directly onto the company balance sheet. Credent Connect N Care has earmarked the net proceeds for four primary areas:

  1. Working Capital Financing (₹38.50 Crore / 41.0%): Healthcare logistics and staffing solutions involve extended payment credit cycles from diagnostic chains and hospital networks. Infusing working capital will support cash flow requirements as revenues scale.
  2. Investment in Operating Subsidiaries (₹22.00 Crore / 23.4%): Injected as equity or loan capital into subsidiaries to expand cold-chain transit infrastructure, fleet tech, and regional hub branches.
  3. Debt Repayment / Prepayment (₹15.00 Crore / 16.0%): Paying down existing bank term loans and working capital borrowings, reducing annual interest overheads.
  4. General Corporate Purposes & Issue Expenses: Supporting general administrative run-rates, technology upgrades, and issue management fees.

6. Valuation Analysis & Peer Group Comparison

At the upper price band cap of ₹189 per share, Credent Connect N Care is priced at a trailing Price-to-Earnings (P/E) multiple of 18.67x based on its restated FY26 PAT of ₹18.45 crore, establishing a post-issue corporate market capitalization of approximately ₹344.41 crore.

Let's compare this with listed logistics, healthcare support, and diagnostic service providers in India:

+-----------------------------------------------------------------------------------+
|                        PEER GROUP VALUATION COMPARISON                            |
+-----------------------------------+--------------------+--------------------------+
| Company Name                      | Trailing P/E (x)   | Primary Focus / Model    |
+-----------------------------------+--------------------+--------------------------+
| Credent Connect N Care (At ₹189)  | ~18.67x            | Healthcare Logistics & B2B|
| Delhivery Limited                 | ~2.45x (P/S)       | Third-Party Logistics    |
| TCI Express Ltd                   | ~28.50x            | Express Cold Logistics   |
| Krsnaa Diagnostics Ltd            | ~36.50x            | PPP Diagnostic Support   |
| Metropolis Healthcare Ltd         | ~54.30x            | Diagnostic Testing Chain |
+-----------------------------------+--------------------+--------------------------+

Valuation Summary:

At 18.67x FY26 trailing earnings, Credent Connect N Care is entering the public market at a disciplined valuation structure. While pure diagnostic chains trade at 36x to 54x P/E and express logistics players trade near 28x P/E, Credent's ~18.7x trailing P/E multiple—combined with ₹214 crore in revenue, 38.3% RoNW, and a 100% fresh issue structure—leaves a healthy fundamental margin of safety for incoming public investors.

7. Core Strengths vs. Key Business Risks

Investors evaluating this SME healthcare logistics issue should consider the following operational factors:

Key Strengths:

  • 100% Fresh Issue Structure: No promoter cash-out; all ₹93.90 crore raised goes into subsidiary investment, working capital, and debt reduction.
  • Blue-Chip Institutional Anchor Book: Sunil Singhania's Abakkus, Motilal Oswal Finvest, and 360 ONE anchor participation signals strong institutional conviction.
  • High Barrier B2B Niche: Operating nationwide cold-chain logistics across 452+ cities creates high entry barriers against generic courier firms.
  • Disciplined Valuation (18.67x P/E): Priced at ~18.7x FY26 earnings, offering an attractive multiple relative to its 174.8% top-line growth.

Key Risk Factors:

  • Customer Concentration Risk: The company's top 10 clients contributed 81.76% of total revenue in FY26. Losing any key diagnostic chain partner could affect sales volumes.
  • Working Capital Intensity & Cash Flows: B2B healthcare contracts carry high trade receivables, resulting in working capital requirements and historically tight operating cash flows.
  • Inorganic Growth vs. Organic Execution: Recent financial scaling was largely supported by subsidiary expansion and consolidation, making ongoing integration execution critical.

8. Application Matrix & Key Timeline

For investors planning to submit applications for the Credent Connect N Care IPO, here is the application breakdown and upcoming timeline:

  • Public Bidding Window Opens: Thursday, August 13, 2026 (Status: Live / Day 1 Complete)
  • Public Bidding Window Closes: Monday, August 17, 2026 (5:00 PM IST)
  • Basis of Allotment Finalization: Tuesday, August 18, 2026
  • Refund Initiations & Unblocking of Bank Funds: Wednesday, August 19, 2026
  • Credit of Equity Shares to Demat Accounts: Wednesday, August 19, 2026
  • Official Stock Exchange Listing (NSE Emerge / SME): Thursday, August 20, 2026
  • Designated Lead Manager: Hem Securities Limited
  • Designated Registrar: KFin Technologies Limited

Application Size Matrix:

  • Retail Minimum & Maximum: 2 Lots (1,200 Shares) — ₹2,26,800
  • Small HNI (sNII) Minimum: 3 Lots (1,800 Shares) — ₹3,40,200
  • Big HNI (bNII) Minimum: 9 Lots (5,400 Shares) — ₹10,20,600

Conclusion: What Should You Watch for on Day 2 & Day 3?

Credent Connect N Care presents a compelling healthcare technology and logistics story backed by its C3 Logistics brand, pan-India presence across 452+ cities, 6,500+ field force, 38.3% RoNW returns, marquee anchor backing (Abakkus, Motilal Oswal), and a disciplined 18.67x trailing P/E entry multiple.

With Day 1 subscription closing at 2.18x overall—supported by 3.11x retail coverage, 1.59x HNI demand, and 1.00x QIB booking—the issue has established strong opening momentum.

Over the next two sessions, watch how wealth and retail categories build up their order blocks ahead of Monday's 5:00 PM closing deadline.

Post Excerpt

A complete Day 1 analysis of the ₹93.90 crore Credent Connect N Care SME IPO. Total subscription reached 2.18x as retail subscribed 3.11x and QIBs fully booked at 1.00x. Read our full review of company financials, C3 Logistics cold-chain moat, blue-chip anchor backers (Abakkus, Motilal Oswal), grey market trends (+₹50), working capital deployment, and valuation ahead of the August 17 close.